Drospirenone Progestogen Compositions With Controlled Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing progestogen-only contraceptives (POCs) suffer from low reliability, altered bleeding patterns, and side effects due to high plasma concentration peaks of drospirenone, which can lead to complications in patients with conditions like hyperkalemia or those who cannot tolerate estrogen.
Innovation Solution
Development of pharmaceutical compositions and kits with novel dosing regimens for drospirenone that allow skipping doses and provide a pharmacokinetic profile with reduced Cmax and delayed tmax, ensuring effective ovulation inhibition and stable plasma concentrations without estrogen, using non-micronized drospirenone with controlled dissolution rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional synthetic progestogens are used in progestogen-only contraceptives, then ovulation inhibition is achieved, but high plasma concentration peaks occur causing side effects like weight gain, breast tension, and poor tolerance
Solution Approach 1:
The patent changes the particle size parameter of drospirenone from micronized (fine particles) to non-micronized (coarse particles with d50 between 10-60 μm). This parameter change fundamentally alters the dissolution kinetics, reducing the rate and extent of absorption, thereby lowering plasma Cmax while maintaining adequate AUC for contraceptive efficacy. This resolves the contradiction by modifying the physical state parameter to eliminate harmful side effects.
Solution Approach 2:
The patent introduces dynamic control over the dissolution rate through controlled particle size distribution. The non-micronized drospirenone provides a dynamic, sustained release profile rather than the static, rapid release of micronized forms. This dynamic dissolution behavior maintains therapeutic levels while avoiding toxic peaks, resolving the reliability-side effect contradiction.
2Ease of manufacture
If drospirenone is administered in micronized form, then rapid dissolution and good oral bioavailability are achieved, but high plasma concentration peaks occur causing undesirable side effects
Solution Approach 1:
The patent fundamentally changes the particle size parameter from micronized to non-micronized drospirenone. This parameter change transforms the dissolution profile from rapid (micronized) to controlled/slow (non-micronized with d50 10-60 μm), thereby reducing plasma Cmax while preserving adequate bioavailability through sustained absorption. This resolves the contradiction between ease of manufacture and harmful effects.
3Object-affected harmful factors
If progestogen-only contraceptives are used to avoid estrogen, then estrogen-related side effects are avoided, but bleeding patterns are deeply altered with amenorrhea or unscheduled bleeding
Solution Approach 1:
The patent changes the dissolution rate parameter of drospirenone through non-micronization, creating a sustained release profile. This parameter change stabilizes plasma concentration fluctuations, which in turn stabilizes the endometrial lining and reduces unscheduled bleeding and amenorrhea. This resolves the contradiction by modifying the release kinetics to improve bleeding pattern stability while maintaining the progestogen-only advantage.
4Reliability
If drospirenone is administered at standard doses, then ovulation inhibition is achieved, but contraceptive reliability is low requiring strict daily adherence without missed doses
Solution Approach 1:
The patent introduces dynamic, sustained release kinetics through non-micronized drospirenone with controlled particle size. This creates a prolonged therapeutic window that maintains ovulation inhibition even when doses are delayed or missed, thereby improving ease of operation and compliance while preserving contraceptive reliability.
Solution Approach 2:
The sustained release profile of non-micronized drospirenone acts as a cushion against dosing errors. The extended half-life and gradual absorption provide a buffer that maintains effective levels during brief interruptions, beforehand protecting against the loss of contraceptive efficacy that would occur with immediate-release formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions offer improved contraceptive reliability, reduced side effects, and better tolerance for patients with conditions like hyperkalemia, maintaining effective contraceptive efficacy even with missed doses, and avoiding estrogen-related risks.
Implementation Method 1
non-micronized drospirenone with controlled dissolution rates
Implementation Method 2
delayed tmax, ensuring effective ovulation inhibition and stable plasma concentrations
Data Source
AI summary
Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.